| Host: |
Rabbit |
| Applications: |
WB/IHC/IF/ELISA |
| Reactivity: |
Human/Rat/Mouse |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase FUT3 (91-140 aa) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
| Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Concentration: |
1 mg/mL |
| Dilution Range: |
WB 1:500-1:2000IHC 1:100-1:300ELISA 1:10000IF 1:50-200 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
FUT3 |
| Gene ID: |
2525 |
| Uniprot ID: |
FUT3_HUMAN |
| Immunogen Region: |
91-140 aa |
| Specificity: |
FucT-III Polyclonal Antibody detects endogenous levels of FucT-III protein. |
| Immunogen: |
The antiserum was produced against synthesized peptide derived from the human FUT3 at the amino acid range 91-140 |
| Post Translational Modifications | Glycosylated. |
| Function | Catalyzes the transfer of L-fucose, from a guanosine diphosphate-beta-L-fucose, to both the subterminal N-acetyl glucosamine (GlcNAc) of type 1 chain (beta-D-Gal-(1->3)-beta-D-GlcNAc) glycolipids and oligosaccharides via an alpha(1,4) linkage, and the subterminal glucose (Glc) or GlcNAc of type 2 chain (beta-D-Gal-(1->4)-beta-D-GlcNAc) oligosaccharides via an alpha(1,3) linkage, independently of the presence of terminal alpha-L-fucosyl-(1,2) moieties on the terminal galactose of these acceptors and participates in the blood groups Lewis determination and expression of Lewis a (Le(a)), lewis b (Le(b)), Lewis x/SSEA-1 (Le(x)) and lewis y (Le(y)) antigens. Also catalyzes the transfer of L-fucose to subterminal GlcNAc of sialyl- and disialyl-lactotetraosylceramide to produce sialyl Lewis a (sLe(a)) and disialyl Lewis a via an alpha(1,4) linkage and therefore may regulate cell surface sialyl Lewis a expression and consequently regulates adhesive properties to E-selectin, cell proliferation and migration. Catalyzes the transfer of an L-fucose to 3'-sialyl-N-acetyllactosamine by an alpha(1,3) linkage, which allows the formation of sialyl-Lewis x structure and therefore may regulate the sialyl-Lewis x surface antigen expression and consequently adhesive properties to E-selectin. Prefers type 1 chain over type 2 acceptors. Type 1 tetrasaccharide is a better acceptor than type 1 disaccharide suggesting that a beta anomeric configuration of GlcNAc in the substrate is preferred. Lewis-positive (Le(+)) individuals have an active enzyme while Lewis-negative (Le(-)) individuals have an inactive enzyme. |
| Protein Name | 3-Galactosyl-N-Acetylglucosaminide 4-Alpha-L-Fucosyltransferase Fut34-Galactosyl-N-Acetylglucosaminide 3-Alpha-L-FucosyltransferaseAlpha-3-Fucosyltransferase Fut3Blood Group Lewis Alpha-4-FucosyltransferaseLewis FtFucosyltransferase 3Fucosyltransferase IiiFuct-Iii |
| Database Links | Reactome: R-HSA-9037629Reactome: R-HSA-975578 |
| Cellular Localisation | Golgi ApparatusGolgi Stack MembraneSingle-Pass Type Ii Membrane ProteinMembrane-Bound Form In Trans Cisternae Of Golgi |
| Alternative Antibody Names | Anti-3-Galactosyl-N-Acetylglucosaminide 4-Alpha-L-Fucosyltransferase Fut3 antibodyAnti-4-Galactosyl-N-Acetylglucosaminide 3-Alpha-L-Fucosyltransferase antibodyAnti-Alpha-3-Fucosyltransferase Fut3 antibodyAnti-Blood Group Lewis Alpha-4-Fucosyltransferase antibodyAnti-Lewis Ft antibodyAnti-Fucosyltransferase 3 antibodyAnti-Fucosyltransferase Iii antibodyAnti-Fuct-Iii antibodyAnti-FUT3 antibodyAnti-FT3B antibodyAnti-LE antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
